Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Gershman MD, Staples JE, Bentsi-Enchill AD, Breugelmans JG, Brito GS, Camacho LA, Cottin P, Domingo C, Durbin A, Gascon J, Guenaneche F, Hayes EB, Jelenik Z, Khromava A, Martins Rde M, Wilson MM, Massy N, Nasidi A, Niedrig M, Sherwat A, Tsai T, Vilella A, Wilson ME, Kohl KS; Brighton Collaboration Viscerotropic Disease Working Group.

Vaccine. 2012 Jul 13;30(33):5038-58. doi: 10.1016/j.vaccine.2012.04.067. Epub 2012 May 4. No abstract available.

2.

Can reporting of adverse drug reactions create safer systems while improving health data?

Hohl C, Lexchin JR, Balka E.

CMAJ. 2015 Aug 11;187(11):789-90. doi: 10.1503/cmaj.150057. Epub 2015 May 4. No abstract available.

3.

Effect of reporting bias in the analysis of spontaneous reporting data.

Ghosh P, Dewanji A.

Pharm Stat. 2015 Jan-Feb;14(1):20-5. doi: 10.1002/pst.1657. Epub 2014 Nov 6.

PMID:
25376637
4.

Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data.

Sejvar JJ, Kohl KS, Bilynsky R, Blumberg D, Cvetkovich T, Galama J, Gidudu J, Katikaneni L, Khuri-Bulos N, Oleske J, Tapiainen T, Wiznitzer M; Brighton Collaboration Encephalitis Working Group.

Vaccine. 2007 Aug 1;25(31):5771-92. Epub 2007 May 11. No abstract available.

PMID:
17570566
5.

Statistical methods for the analysis of adverse event data.

Kieser M.

Pharm Stat. 2016 Jul;15(4):290-1. doi: 10.1002/pst.1759. Epub 2016 Jun 20. No abstract available.

PMID:
27324410
6.

Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area.

Grundmark B, Holmberg L, Garmo H, Zethelius B.

Eur J Clin Pharmacol. 2014 May;70(5):627-35. doi: 10.1007/s00228-014-1658-1. Epub 2014 Mar 7.

7.

Surveillance of adverse events following immunization in China: Past, present, and future.

Liu D, Wu W, Li K, Xu D, Ye J, Li L, Wang H.

Vaccine. 2015 Jul 31;33(32):4041-6. doi: 10.1016/j.vaccine.2015.04.060. Epub 2015 Apr 28. Review.

PMID:
25936727
8.

The development of standardized case definitions and guidelines for adverse events following immunization.

Kohl KS, Gidudu J, Bonhoeffer J, Braun MM, Buettcher M, Chen RT, Drammeh B, Duclos P, Heijbel H, Heininger U, Hummelman E, Jefferson T, Keller-Stanislawski B, Loupi E, Marcy SM.

Vaccine. 2007 Aug 1;25(31):5671-4. Epub 2007 Mar 12. No abstract available.

PMID:
17400339
9.

Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.

Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, de Souza Brito G, Heininger U, Imoukhuede B, Khamesipour A, Erlewyn-Lajeunesse M, Martin S, Mäkelä M, Nell P, Pool V, Simpson N; Brighton Collaboration Anaphylaxis Working Group.

Vaccine. 2007 Aug 1;25(31):5675-84. Epub 2007 Mar 12. No abstract available.

PMID:
17448577
10.

Fatigue: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Jones JF, Kohl KS, Ahmadipour N, Bleijenberg G, Buchwald D, Evengard B, Jason LA, Klimas NG, Lloyd A, McCleary K, Oleske JM, White PD; Brighton Collaboration Fatigue Working Group.

Vaccine. 2007 Aug 1;25(31):5685-96. Epub 2007 Mar 12. No abstract available.

PMID:
17400340
11.

Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Wise RP, Bonhoeffer J, Beeler J, Donato H, Downie P, Matthews D, Pool V, Riise-Bergsaker M, Tapiainen T, Varricchio F; Brighton Collaboration Thrombocytopenia Working Group.

Vaccine. 2007 Aug 1;25(31):5717-24. Epub 2007 Mar 12. No abstract available.

PMID:
17493712
12.

Applicability of the Brighton Collaboration Case Definition for seizure after immunization in active and passive surveillance in Canada.

Top KA, Constantinescu CM, Laflèche J, Bettinger JA, Scheifele DW, Vaudry W, Halperin SA, Law BJ.

Vaccine. 2013 Nov 19;31(48):5700-5. doi: 10.1016/j.vaccine.2013.09.048. Epub 2013 Oct 5.

PMID:
24099871
13.

Abscess at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Kohl KS, Ball L, Gidudu J, Hammer SJ, Halperin S, Heath P, Hennig R, Labadie J, Rothstein E, Schuind A, Varricchio F, Walop W; Brighton Collaboration Local Reactions Working Group for Abscess at Injection Site.

Vaccine. 2007 Aug 1;25(31):5821-38. Epub 2007 May 11. No abstract available.

PMID:
17540485
14.

Cellulitis at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Halperin S, Kohl KS, Gidudu J, Ball L, Hammer SJ, Heath P, Hennig R, Labadie J, Rothstein E, Schuind A, Varricchio F, Walop W; Brighton Collaboration Local Reaction Working Group for Cellulitis at Injection Site.

Vaccine. 2007 Aug 1;25(31):5803-20. Epub 2007 May 11. No abstract available.

PMID:
17548135
15.

Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Kohl KS, Walop W, Gidudu J, Ball L, Halperin S, Hammer SJ, Heath P, Hennig R, Rothstein E, Schuind A, Varricchio F; Brighton Collaboration Local Reactions Working Group for Induration at or near Injection Site.

Vaccine. 2007 Aug 1;25(31):5839-57. Epub 2007 May 8. No abstract available.

PMID:
17553602
16.

Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data.

Kohl KS, Walop W, Gidudu J, Ball L, Halperin S, Hammer SJ, Heath P, Varricchio F, Rothstein E, Schuind A, Hennig R; Brighton Collaboration Local Reaction Working Group for Swelling at or near Injection Site.

Vaccine. 2007 Aug 1;25(31):5858-74. Epub 2007 May 11. No abstract available.

PMID:
17548132
17.

Rash including mucosal involvement: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Beigel J, Kohl KS, Khuri-Bulos N, Bravo L, Nell P, Marcy SM, Warschaw K, Ong-Lim A, Poerschke G, Weston W, Lindstrom JA, Stoltman G, Maurer T; Brighton Collaboration Rash Working Group.

Vaccine. 2007 Aug 1;25(31):5697-706. Epub 2007 Mar 13. No abstract available.

PMID:
17403561
18.

Progressive vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data.

Nell P, Kohl KS, Graham PL, LaRussa PS, Marcy SM, Fulginiti VA, Martin B, McMahon A, Norton SA, Trolin I; Brighton Collaboration Vaccinia Virus Vaccine Adverse Event Working Group for Progressive Vaccinia.

Vaccine. 2007 Aug 1;25(31):5735-44. Epub 2007 May 4. No abstract available.

PMID:
17540484
19.

Generalized vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.

Beigel J, Kohl KS, Brinley F, Graham PL, Khuri-Bulos N, LaRussa PS, Nell P, Norton S, Stoltman G, Tebaa A, Warschaw K; Brighton Collaboration Vaccinia Virus Vaccine Adverse Event Working Group for Generalized Vaccinia.

Vaccine. 2007 Aug 1;25(31):5745-53. Epub 2007 May 2. No abstract available.

PMID:
17537552
20.

Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study.

Gold MS, Gidudu J, Erlewyn-Lajeunesse M, Law B; Brighton Collaboration Working Group on Anaphylaxis.

Vaccine. 2010 Jun 17;28(28):4487-98. doi: 10.1016/j.vaccine.2010.04.041. Epub 2010 Apr 29.

PMID:
20434547

Supplemental Content

Support Center